Subsequent disease progression revealed the emergence of a secondary <i>MET</i> mutation, specifically MET Y1230H, leading to acquired resistance to crizotinib.<h4>Conclusion</h4>The reporting of this case is imperative for informing clinical practice, given the uncommon occurrence of NSCLC with <i>MET</i> fusion, displaying responsiveness to MET tyrosine kinase inhibitor therapy, as well as the emergence of the secondary Y1230H alteration as a potential resistance mechanism. The gene discussed is MET; the disease is non-small cell lung carcinoma.